Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Earlier, Terns Pharmaceuticals Prices Upsized $150.15M Public Offering Of 11,919,048 At $10.50/Share

Author: Benzinga Newsdesk | September 11, 2024 02:24am

Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufacturing of the Company's key product candidates, including TERN-701, TERN-601 and other programs, including Terns' TERN-800 series, and for working capital and general corporate purposes.

Posted In: TERN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist